Real-World Analysis of Breast Cancer Patients Reveals Significant Findings on Adjuvant Therapy Efficacy

Strategic Insights -

According to a recent study published in ESMO Open, a significant proportion of patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) early breast cancer (EBC) are eligible for adjuvant ribociclib (NATALEE) and abemaciclib (monarchE) therapy, demonstrating a potential invasive disease survival benefit when added to standard-of-care adjuvant endocrine therapy (ET) and chemotherapy. The study analyzed data from the ConcertAI Patient360 database, covering January 2015 to January 2023, and included 7,060 patients who met the inclusion criteria.

Key Takeaways:

  • The study found that 30.6% of patients with HR+/HER2- EBC met the eligibility criteria for NATALEE, while 14.5% were eligible for monarchE.
  • The majority of patients with N0 disease (74.9% of the population) were ineligible for monarchE, while 9.5% were eligible for NATALEE.
  • Among patients with N1 disease, 91.8% were eligible for NATALEE, while 45.9% were eligible for monarchE.
  • Patients with high-risk N0 disease who were eligible for NATALEE were predominantly postmenopausal (72.6%), had a grade 3 tumor (61.6%), and had received prior chemotherapy (48.9%).
  • The study's results indicate that nearly one-third of patients with HR+/HER2- EBC at high risk of recurrence may benefit from NATALEE or monarchE therapy.

Statistics:

  • 7,060 patients met the inclusion criteria for the study.
  • 30.6% of patients were eligible for NATALEE.
  • 14.5% of patients were eligible for monarchE.
  • Among patients with N1 disease, 91.8% were eligible for NATALEE.
  • 74.9% of patients with N0 disease were ineligible for monarchE.
  • 48.9% of patients with high-risk N0 disease who were eligible for NATALEE had received prior chemotherapy.

Sources:

  • NewsRx. Dana-Farber Cancer Institute Reports Findings in Breast Cancer (Characteristics of real-world NATALEE- and monarchE-eligible populations with HR+/HER2- early breast cancer: a United States Electronic Health Records database analysis). Information Technology Newsweekly. July 1, 2025; p 98.
  • ESMO Open. Characteristics of real-world NATALEE- and monarchE-eligible populations with HR+/HER2- early breast cancer: a United States Electronic Health Records database analysis. 2025;10(6):105304.